Preclinical evaluation of the CAD siramesine revealed its ability to induce LMP and tumor-selective cell death [21] hinging on displacement of the lipid-metabolizing enzyme acid sphingomyelinase (ASM) from its lipid cofactor bis(monoacylglycero)phosphate (BMP), thereby inhibiting hydrolysis of sphingomyelin to ceramide and disrupting membrane dynamics due to sphingomyelin accumulation [24]. Here, PDLIM7 is linked to neoplasm.